Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOB015B Phase 3 trial in distal subungual onychomycosis
2016-001204-39Phase 3Completed
- Sponsor
- Moberg Pharma AB
- Start
- Jun 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Terclara in onychomycosis (2 arms), sponsored by Moberg Pharma AB. Primary endpoint: Complete cure at Week 52. Started Jun 2016; status: completed.
02
Drugs
Terclara
03
Conditions
onychomycosis
Beyond the preview
Go deeper on 2016-001204-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001204-39.